Development Level

Tclin 4 | 602
Tbio 1 | 10,625
Tchem 1 | 1,890

Disease

ovarian cancer 5 | 8,484
Cervical ripening procedure 4 | 9
Hydatidiform mole, benign 4 | 9
Incomplete miscarriage 4 | 10
Induction of labor 4 | 10
Pregnancy with abortive outcome 4 | 12
Cancer 3 | 2,346
Physiological Sexual Disorders 3 | 4
intraductal papillary-mucinous neoplasm (IPMN) 3 | 3,289
invasive ductal carcinoma 3 | 2,950
osteosarcoma 3 | 7,933
psoriasis 3 | 6,685
Aorta Dextratransposition with Intact Ventricular Septum 2 | 6
Breast cancer 2 | 3,094
Coarctation of aorta 2 | 6
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus 2 | 6
Congenital atresia of the pulmonary valve 2 | 6
Congenital atresia of tricuspid valve 2 | 6
Crohn's disease 2 | 304
Ebstein's anomaly of tricuspid valve 2 | 6
Endometriosis 2 | 535
Impotence 2 | 45
Pulmonary artery stenosis 2 | 6
Tetralogy of Fallot 2 | 35
Vascular disease 2 | 281
adrenocortical adenoma 2 | 134
adrenocortical carcinoma 2 | 1,427
aldosterone-producing adenoma 2 | 664
colon cancer 2 | 1,475
cystic fibrosis 2 | 1,665
glioblastoma 2 | 5,572
interstitial cystitis 2 | 2,299
intraductal papillary-mucinous adenoma (IPMA) 2 | 2,956
intraductal papillary-mucinous carcinoma (IPMC) 2 | 2,988
lung adenocarcinoma 2 | 2,713
lung cancer 2 | 4,466
lung carcinoma 2 | 2,844
non-small cell lung cancer 2 | 2,798
pilocytic astrocytoma 2 | 3,086
pituitary cancer 2 | 1,972
posterior fossa group B ependymoma 2 | 1,530
primary Sjogren syndrome 2 | 789
ulcerative colitis 2 | 2,087
ASTHMA, ASPIRIN-INDUCED, SUSCEPTIBILITY TO 1 | 2
Adenocarcinoma 1 | 115
Allergic rhinitis 1 | 91
Animal Mammary Neoplasms 1 | 136
Ankylosing spondylitis 1 | 138
Arthritis 1 | 248
Arthritis, Experimental 1 | 39
Asthma, Aspirin-Induced 1 | 13
Asthma, Nasal Polyps, And Aspirin Intolerance 1 | 2
Atopic dermatitis 1 | 944
Bipolar Disorder 1 | 266
Brain cancer 1 | 21
Chagas disease 1 | 34
Chloracne 1 | 32
Common cold 1 | 63
Conjunctivochalasis 1 | 6
Cough 1 | 21
Diabetes Mellitus, Experimental 1 | 106
Down syndrome 1 | 548
Drug allergy 1 | 36
Gaucher disease type 3 1 | 76
Gout 1 | 93
Hyperalgesia 1 | 71
IGA Glomerulonephritis 1 | 454
Infertility 1 | 163
Inflammation 1 | 109
Inflammatory bowel disease 1 | 142
Keshan disease 1 | 14
Lactic acidosis 1 | 42
Lupus erythematosus 1 | 80
Lymphoma 1 | 56
Malaria 1 | 140
Malignant glioma 1 | 23
Mammary Neoplasms, Experimental 1 | 150
Multiple Sclerosis 1 | 498
Muscle Weakness 1 | 92
Nasal congestion 1 | 24
Neuroblastoma 1 | 78
Ocular hypertension 1 | 27
Polycystic Ovary Syndrome 1 | 332
Pulmonary hypertension 1 | 52
Rhinitis 1 | 46
Squamous cell carcinoma 1 | 94
Stevens-Johnson syndrome 1 | 78
Tularemia 1 | 22
autosomal dominant Emery-Dreifuss muscular dystrophy 1 | 499
breast carcinoma 1 | 1,614
chronic lymphosyte leukemia 1 | 232
dermatomyositis 1 | 933
esophageal adenocarcinoma 1 | 737
head and neck cancer and chronic obstructive pulmonary disease 1 | 237
hepatocellular carcinoma 1 | 532
medulloblastoma 1 | 1,524
mucosa-associated lymphoid tissue lymphoma 1 | 480
pulmonary arterial hypertension 1 | 36
sarcoidosis 1 | 358
tuberculosis 1 | 1,557

Tissue

Blood and immune system 6 | 17,995
Cardiovascular System 6 | 17,958
Digestive Tract 6 | 18,473
Endocrine System 6 | 18,512
Female tissues 6 | 18,647
Liver and Pancreas 6 | 18,136
Male tissues 6 | 17,969
Nervous System 6 | 18,561
Respiratory system 6 | 17,484
Skin and soft tissues 6 | 18,115
Urinary Tract 6 | 18,444

Target Family

GPCR 4 | 406
Enzyme 1 | 4,146
Non-IDG 1 | 11,971

Grant Application

1R21HD066248-01A1 6 | 6
3P41RR001209-23S1 157 | 157
5P41RR001209-22 157 | 157
5P41RR001209-23 157 | 157
2P51RR000165-51 139 | 139
5P51RR000163-52 136 | 136
5P51RR000163-51 132 | 132
5P51RR000165-50 130 | 130
2P51RR000163-50 128 | 128
5P51RR000164-48 127 | 127
5P51RR000164-50 125 | 125
5P51RR000164-49 112 | 112
5P51RR000165-49 106 | 106
5P41RR001646-19 103 | 103
5P41RR001646-20 103 | 103
7P51RR000163-41 100 | 100
2P41RR011823-16 99 | 99
5P51RR000163-42 98 | 98
5P51RR000163-43 98 | 98
5P41RR001081-24 94 | 94
5P41RR001646-18 90 | 90
5P41RR015301-09 82 | 82
5P51RR000167-49 78 | 78
5P41RR002250-26 65 | 65
5P51RR000168-40 65 | 65
5P51RR000168-41 65 | 65
5P41RR001646-27 64 | 64
5P51RR000165-40 63 | 63
5M01RR000188-45 60 | 60
3P41RR010888-05S1 59 | 59
5M01RR000030-40 58 | 58
5M01RR000096-39 57 | 57
5P41RR000954-25 57 | 57
5P41RR000954-26 57 | 57
2P41RR000954-33 56 | 56
5P41RR010888-14 56 | 56
5P41RR012408-13 55 | 55
5M01RR000188-46 53 | 53
5P41RR001646-28 52 | 52
5P51RR000167-48 52 | 52
5P51RR000168-49 52 | 52
5P41RR001646-29 51 | 51
2P41RR002250-25 50 | 50
5M01RR000188-47 50 | 50
5P51RR000166-39 47 | 47
5M01RR000043-40 46 | 46
5P51RR000168-50 46 | 46
5P41RR010888-15 45 | 45
5P41RR015301-08 45 | 45
5P41RR004050-13 44 | 44
5M01RR000847-37 43 | 43
5P41RR004050-12 43 | 43
5P51RR000167-50 43 | 43
5P51RR000169-50 43 | 43
5P41RR000954-34 42 | 42
2P41RR004050-21 41 | 41
5P41RR010888-13 41 | 41
5P51RR000168-48 41 | 41
5P51RR000167-40 40 | 40
5P41RR015301-07 39 | 39
5P51RR000164-39 39 | 39
5P51RR000168-39 39 | 39
2P51RR000169-49 38 | 38
5P51RR000169-48 38 | 38
5P41RR004050-23 37 | 37
5P51RR013986-13 37 | 37
3P51RR000167-46S2 36 | 36
5P41RR001008-25 36 | 36
5M01RR000043-49 35 | 35
5P20RR021905-04 35 | 35
5P41RR004050-22 35 | 35
5M01RR000040-40 34 | 34
5P20RR016481-10 34 | 34
5P41RR001315-19 34 | 34
3P60DE013079-01S1 32 | 32
5M01RR000833-26 32 | 32
5P20RR016481-11 32 | 32
5P20RR020152-07 32 | 32
5P41RR000862-38 32 | 32
5P51RR000166-49 32 | 32
5P60DE013079-02 32 | 32
5S06GM008037-29 32 | 32
5S06GM008037-30 32 | 32
5U41RR007707-10 32 | 32
2P20RR016480-09 31 | 31
5M01RR000827-34 31 | 31
5P41RR002250-24 31 | 31
5P41RR005959-22 31 | 31
5P41RR018522-08 31 | 31
3P60DE013079-03S1 30 | 30
5P20RR016457-10 30 | 30
5P41RR000592-40 30 | 30
5P41RR000592-41 30 | 30
5P41RR000862-36 30 | 30
5P41RR007707-17 30 | 30
5P51RR000166-48 30 | 30
5P60DE013079-03 30 | 30
5P60DE013079-04 30 | 30
5U54AI057168-09 30 | 30
5U54AI057168-10 30 | 30
2U54AI057168-06 29 | 29

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Cytochrome c oxidase subunit 2 MT-CO2 Tchem Enzyme -2.93191 857.2 116
Interferon-inducible protein AIM2 AIM2 Tbio Non-IDG -2.26799 140.7 401
Prostaglandin E2 receptor EP4 subtype PTGER4 Tclin GPCR -2.94537 922.9 216
Prostaglandin E2 receptor EP1 subtype PTGER1 Tclin GPCR -2.62426 387.2 160
Prostaglandin E2 receptor EP3 subtype PTGER3 Tclin GPCR -2.77018 604.1 294
Prostaglandin E2 receptor EP2 subtype PTGER2 Tclin GPCR -1.20146 15.1 372